

Patented Technology for Enhanced Cannabis Delivery to the Skin



OVATION
SCIENCE INC.

Focused on bringing real science to the global cannabis space with its topical & transdermal products all powered by its unique, patented delivery system Invisicare®.

CSE: OVAT

COMPANY HIGHLIGHTS

OUR PRODUCTS:



NEW – DERMSAFE®: DermSafe® is a hand sanitizer lotion made with chlorhexidine gluconate; an ingredient proven to be effective at killing both bacteria and viruses. Feb 2020 – Ovation received its first order of 25,000 bottles to be exported to China to help combat the coronavirus epidemic. Additional orders in discussion.

INVIBE® MD: Our Health & Wellness line Invibe® MD is enhanced with hemp-derived CBD and delivered by patented INVISICARE® skin technology. Products include Relief & Relax, Troubled Skin and Keep Fit Sports Cream.

ARLO CBD BEAUTY: Our anti-aging product line, available in the US, helps fight the signs of aging with a rejuvenating day cream, a renewing night cream, a restoring eye cream as well as a super moisturizing hand & body lotion, with more products to come. Products were developed using proven anti-aging ingredients with scientific evidence of their effectiveness at reducing the effects of aging, all enhanced with the power of CBD from hemp and delivered by Invisicare® drug delivery technology.

US LICENSEE: Our US licensee *Lighthouse Strategies, LLC*, has launched 4 Ovation products in Nevada & California under the brand name “BASKiN”, with products already being awarded the “Best High-Dose CBD Topical” designation in Nevada by Leafly as well as “the world’s first recreational cream” called BASKiN GLOW (50mg CBD+500mgTHC) & in 2019 was the #1 selling topical product (by # of units) in Nevada dispensaries (Headset.io).

OUR SCIENCE:

All products developed using Ovation’s Invisicare® patent delivery system are developed using pharmaceutical-grade development processes and backed by 20+ years of science;

Our highly effective formulations are designed to deliver cannabis both topically and transdermally (into the blood stream) and studies prove we provide a greater release and penetration of active ingredients to and through the skin; up to five times greater than brand leaders tested.

OUR PATENTS:

OVATION’s products are protected by comprehensive patent protection in 11 countries including the United States and Canada. Ovation has also filed a provisional patent for its transdermal delivery of cannabis.

BUSINESS MODEL:

Ovation will generate online and wholesale revenue from DermSafe®, ARLO CBD Beauty product line & our Invibe® MD medical/ wellness line. Ovation’s out-licensing business model generates revenue from multiple revenue streams including development fees, licensing fees, on-going royalties based on revenues and sales of Invisicare polymer to its licensees.

THE POTENTIAL:

The cannabis market potential is global for countries / states where medical marijuana and/or adult-use is legalized and the CBD skincare (hemp) market is estimated to grow to \$25 billion globally in the next decade. Additionally, Ovation has the opportunity to sell its hand sanitizer in countries where it is approved including Canada.

FUTURE GROWTH:

To continue to grow revenues, Ovation Science is investing in marketing, business development, new product development and infra-structure:

- Ovation is poised to capture a large share of the topical CBD market in the US and globally where approved;
- Expand its licensees for Ovation's topical and transdermal products both in the US and globally;
- Partner with a pharmaceutical company to develop synthetic marijuana products (i.e. Synthetic THC/CBD);
- License products into the highly lucrative animal health market (i.e. CBD creams for pain management).

OVATION SHARES:

Ovation Science Inc.	# of SHARES	RESERVE	FULLY DILUTED
SHARES OUTSTANDING	23,150,000	6,750,000	29,905,454

CSE: OVAT

DERMATOLOGY ADVISORY BOARD:

Ovation has formed a Medical Dermatology Advisory Board for cannabis formulated products with a team of prominent dermatologists including: chaired by Dr. Chuck Lynde (University of Toronto), Dr. Jeffrey Dover (Yale University), Dr. Leon Kircik (Indiana University) & Dr. Richard Thomas (Sidra Hospital and Research Centre for Women and Children in Doha, Qatar). The objective of the Advisory Board is to reinforce the science behind Ovation's products by providing clinical, scientific, research and strategic advice to the Company as it continues to advance its topical and transdermal cannabis product development and to maintain and support the Company's advantage in the topical cannabis market globally.

MANAGEMENT & DIRECTORS:

OVATION has a team with decades of experience in business development and financial markets and over 75 years of combined experience in dermatology, product research & development:

- **Terry Howlett, President & CEO, Director.** Over 35 years of entrepreneurial, business management and public market initialization experience in the pharmaceutical and skincare markets.
- **Doreen McMorran, Chief Operating Officer, Director.** Over 25 years of experience in the medical and pharmaceutical industry, specifically in the areas of strategic planning, sales and marketing of dermatology products.
- **Logan B. Anderson, CFO, Director.** An experienced financial and management expert with over 30 years of public market experience.
- **David Ryan, Director.** Has extensive experience in investment and public markets. For the past 25 years he has been instrumental in bringing multiple Initial Public Offerings to market.
- **Ian Howard, Director.** Over 40 years of extensive experience in marketing, government and health care as well as over 25 years of business experience with Fortune 500 companies internationally.
- **Joan Chypyha, Director.** A pharmaceutical executive with over 25 years in senior management positions including General Manager of a TSX listed company.
- **James Roszell, PhD, Head of Product Development.** A doctoral chemist & developer of Invisicare®, with over 40 yrs experience in product formulation, experimental design, analysis, and method validation.

For more information contact:

Terry Howlett, President: terry@ovationscience.com or Dave Ryan, IR & Director: dave@ovationscience.com Phone 604.283.0903

OVATION is an ancillary supplier to the cannabis industry, supplying its polymer delivery system Invisicare® and licenses its formulations. (It does not sell any components containing marijuana.) Ovation does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, projections and assumptions about future events. Although Ovation Science Inc. believes that these expectations, projections, and assumptions are reasonable, these forward-looking statements are subject to risks, uncertainties and assumptions about its business operations. As such, the forward-looking events referred to in this document may not occur and actual results may differ materially from those expressly or impliedly anticipated in these forward-looking statements. Investors are advised not to place undue reliance on these forward-looking statements. **NOT FOR DISSEMINATION IN THE USA.**

Copyright 2019 © Ovation Science Inc., All Rights Reserved. www.ovationscience.com

www.ovationscience.com